Roth Capital Reiterates Buy on Bioage Labs, Maintains $25 Price Target

Benzinga · 1d ago
Roth Capital analyst Adam Walsh reiterates Bioage Labs (NASDAQ:BIOA) with a Buy and maintains $25 price target.